Boehringer Sues Drugmakers To Block Generic Gilotrif Plans
By Bonnie Eslinger (October 20, 2017, 11:25 PM EDT) -- German drugmaker Boehringer Ingelheim Pharmaceuticals Inc. filed a pair of patent infringement suits Friday in New Jersey federal court over bids by Sandoz Inc. and Sun Pharmaceutical Industries to market generic versions of its cancer therapy drug.
The suits seek from the court declaratory judgments of patent infringement, along with injunctions to prevent the generic-drug makers from selling or importing their versions of Gilotrif. Boehringer also seeks damages and attorneys' fees.
Boehringer is the maker of Gilotrif, a product used in the treatment of metastatic non-small cell lung cancer. On the drugmaker's website, it states that patients taking Gilotrif "experienced an...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!